Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuki Tsuji

Showing results (31-40 of 103) with videos related to

Pageof 11
Sort By:
Clinical Journal of Gastroenterology|June 30, 2022
Long-term survival with sorafenib-based multidisciplinary treatment for Vp4 hepatocellular carcinoma: a case reportHibiki Narita, Hideto Kawaratani, Akihiko Shibamoto, et al.
BMC Gastroenterology|July 9, 2021
Small intestinal follicular lymphoma induced by methotrexate: a case reportYui Osaki, Hideto Kawaratani, Hiroki Kachi, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|June 5, 2023
Glucagon-like peptide-1 receptor agonist, semaglutide attenuates chronic liver disease-induced skeletal muscle atrophy in diabetic miceSatoshi Iwai, Kosuke Kaji, Norihisa Nishimura, et al.
Microorganisms|June 25, 2020
Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic SteatohepatitisYuki Tsuji, Kosuke Kaji, Mitsuteru Kitade, et al.
Biology|February 25, 2023
The Ratio of von Willebrand Factor Antigen to ADAMTS13 Activity: Usefulness as a Prognostic Biomarker in Acute-on-Chronic Liver FailureHiroaki Takaya, Tadashi Namisaki, Masahide Enomoto, et al.
World Journal of Gastroenterology|August 2, 2024
Effects of elafibranor on liver fibrosis and gut barrier function in a mouse model of alcohol-associated liver diseaseAritoshi Koizumi, Kosuke Kaji, Norihisa Nishimura, et al.
International Journal of Molecular Medicine|June 10, 2022
Rifaximin enhances the L‑carnitine‑mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut‑liver‑muscle axisKoji Murata, Kosuke Kaji, Norihisa Nishimura, et al.
The Journal of Nutritional Biochemistry|September 30, 2023
Vitamin D deficiency exacerbates alcohol-related liver injury via gut barrier disruption and hepatic overload of endotoxinAkihiko Shibamoto, Kosuke Kaji, Norihisa Nishimura, et al.
International Journal of Molecular Sciences|July 29, 2025
Rifaximin Attenuates Liver Fibrosis and Hepatocarcinogenesis in a Rat MASH Model by Suppressing the Gut-Liver Axis and Epiregulin-IL-8-Associated AngiogenesisNaoki Nishimura, Kosuke Kaji, Norihisa Nishimura, et al.
Heliyon|October 14, 2024
Cabozantinib prevents the progression of metabolic dysfunction-associated steatohepatitis by inhibiting the activation of hepatic stellate cell and macrophage and attenuating angiogenic activityTakuya Matsuda, Kosuke Kaji, Norihisa Nishimura, et al.
Pageof 11

Showing results (31-40 of 103) with videos related to

Sort By:
Pageof 11
Clinical Journal of Gastroenterology|June 30, 2022
Long-term survival with sorafenib-based multidisciplinary treatment for Vp4 hepatocellular carcinoma: a case reportHibiki Narita, Hideto Kawaratani, Akihiko Shibamoto, et al.
BMC Gastroenterology|July 9, 2021
Small intestinal follicular lymphoma induced by methotrexate: a case reportYui Osaki, Hideto Kawaratani, Hiroki Kachi, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|June 5, 2023
Glucagon-like peptide-1 receptor agonist, semaglutide attenuates chronic liver disease-induced skeletal muscle atrophy in diabetic miceSatoshi Iwai, Kosuke Kaji, Norihisa Nishimura, et al.
Microorganisms|June 25, 2020
Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic SteatohepatitisYuki Tsuji, Kosuke Kaji, Mitsuteru Kitade, et al.
Biology|February 25, 2023
The Ratio of von Willebrand Factor Antigen to ADAMTS13 Activity: Usefulness as a Prognostic Biomarker in Acute-on-Chronic Liver FailureHiroaki Takaya, Tadashi Namisaki, Masahide Enomoto, et al.
World Journal of Gastroenterology|August 2, 2024
Effects of elafibranor on liver fibrosis and gut barrier function in a mouse model of alcohol-associated liver diseaseAritoshi Koizumi, Kosuke Kaji, Norihisa Nishimura, et al.
International Journal of Molecular Medicine|June 10, 2022
Rifaximin enhances the L‑carnitine‑mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut‑liver‑muscle axisKoji Murata, Kosuke Kaji, Norihisa Nishimura, et al.
The Journal of Nutritional Biochemistry|September 30, 2023
Vitamin D deficiency exacerbates alcohol-related liver injury via gut barrier disruption and hepatic overload of endotoxinAkihiko Shibamoto, Kosuke Kaji, Norihisa Nishimura, et al.
International Journal of Molecular Sciences|July 29, 2025
Rifaximin Attenuates Liver Fibrosis and Hepatocarcinogenesis in a Rat MASH Model by Suppressing the Gut-Liver Axis and Epiregulin-IL-8-Associated AngiogenesisNaoki Nishimura, Kosuke Kaji, Norihisa Nishimura, et al.
Heliyon|October 14, 2024
Cabozantinib prevents the progression of metabolic dysfunction-associated steatohepatitis by inhibiting the activation of hepatic stellate cell and macrophage and attenuating angiogenic activityTakuya Matsuda, Kosuke Kaji, Norihisa Nishimura, et al.
Pageof 11